Risk for Death From Prostate Cancer Low With Guideline Care for Nonmetastatic Disease

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 14, 2025.

via HealthDay

MONDAY, July 14, 2025 -- Men with nonmetastatic prostate cancer receiving guideline-concordant care have a much higher risk for death from causes other than prostate cancer, according to a study published online July 10 in the Journal of the National Comprehensive Cancer Network.

Pietro Scilipoti, M.D. from Uppsala University in Sweden, and colleagues followed men with nonmetastatic prostate cancer, registered in the National Prostate Cancer Register of Sweden from 2000 to 2020, who received primary treatment according to the National Comprehensive Cancer Network (NCCN) Guidelines until Dec. 31, 2022. The risk for mortality from prostate cancer and other causes was estimated up to 30 years according to risk category and life expectancy.

Overall, 62,839 men received primary treatment according to the NCCN Guidelines. The researchers found that per risk category, the simulated 15-year prostate cancer mortality ranged from 5.5 to 22 percent in men with low-risk and very high-risk cancer, respectively. Simulated 30-year prostate cancer mortality varied from 12 to 30 percent in men with low-risk and very high-risk cancer, respectively, while death from other causes varied from 77 to 63 percent.

"Our data support adherence to guideline recommendations for treatment of prostate cancer," Scilipoti said in a statement. "If guideline-recommended treatment is used, most people with prostate cancer will live for many years after diagnosis. That includes active surveillance as an excellent treatment strategy for appropriately selected people."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-15 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords